Vitiligo Successfully Treated With Roflumilast Cream 0.3%
Journal of Drugs in Dermatology · 2026-07-01 · 25 (7) · 662-663
DOI: 10.36849/jdd.9990 ↗At a glance
Fallbericht in Journal of Drugs in Dermatology, published online on 2026-06-01. Written by Maninder Longowal and 1 co-authors. Major MEDLINE topics: Aminopyridines, Benzamides, Vitiligo.
Abstract (original language)
Vitiligo is an autoimmune cutaneous depigmenting disorder that can have significant psychological impacts on affected patients, posing a burden to daily life, which can be even more apparent in patients with deeper Fitzpatrick skin tones. Here we report the case of an adult patient with skin of color treated with roflumilast cream 0.3% following an unsatisfactory response to typical treatments. Treatment resulted in almost full repigmentation on the forehead and cheeks. This case suggests that roflumilast cream 0.3% may have a positive therapeutic effect for patients with vitiligo who are unresponsive to other conventional therapies. .
Subjects
MeSH terms (MEDLINE)
Substances
Cite
APA
Longowal, M., & Maruschak-Love, S. O. (2026). Vitiligo Successfully Treated With Roflumilast Cream 0.3%. Journal of Drugs in Dermatology, 25(7), 662-663. https://doi.org/10.36849/jdd.9990
Vancouver
Longowal M, Maruschak-Love SO. Vitiligo Successfully Treated With Roflumilast Cream 0.3%. Journal of Drugs in Dermatology. 2026;25(7):662-663. doi:10.36849/jdd.9990
BibTeX
@article{Longowal2026,
author = {Longowal, Maninder and Maruschak-Love, Sofia O},
title = {Vitiligo Successfully Treated With Roflumilast Cream 0.3%},
journal = {Journal of Drugs in Dermatology},
year = {2026},
volume = {25},
number = {7},
pages = {662--663},
doi = {10.36849/jdd.9990}
}
EUVIMED